$IRON

Quisel John D sold $2.4M of IRON

Quisel John D (Chief Executive Officer) sold 34,000 shares of Disc Medicine, Inc. (IRON) at an average of $70.21 ($69.92–$71.61, $2.39M total) across 3 trades on 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Quisel John D
Published Jun 23, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRON
Neutral
medium confidence
Mentioned
$IRON
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

The newest fact is the CEO’s disclosed open-market sale of 34,000 shares (~$2.39M) at a weighted average ~$70.21/share, with a stated 10b5-1 pre-arranged plan.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone does not change the company’s fundamentals.

03

What to watch

The filing does not disclose reasons for sale, and the trades occurred on 2026-06-18—any market reaction on 6/23 would be about disclosure timing, not new fundamentals.

Relevance 5/10Novelty 5/10Timing: filed after-hours on 2026-06-23; reflects trades dated 2026-06-18

Background

The article is an SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON).

Company-level read

Ticker impact

$IRONNeutralMedium confidence
Context

SEC Form 4 shows CEO John D Quisel sold 34,000 shares of IRON for ~$2.39M at ~$70.21/share under a 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any effect is more sentiment/positioning than new company fundamentals.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is explicitly under a 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may be routine liquidity management rather than a bearish signal.

Key entities

  • IRON

    Disc Medicine, Inc.; subject of the Form 4 insider sale disclosure.

  • Quisel John D

    CEO and officer/director who sold shares.

  • 10b5-1 plan

    Pre-arranged plan noted as Yes, which typically reduces interpretive signal.

Related articles

$IRONMed

Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 iron-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update • Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis f

$NEEMed

SMALL-CAP MOVERS: Britain's bargain basement and the overseas buyers who can't believe their luck

The article reports AIM takeover activity: Gooch & Housego PLC is being acquired in a £346m deal, and Ramsdens Holdings PLC is set to be bought for £230m. It also notes NextEnergy Solar rose 10% after putting itself up for sale, and highlights large AIM share moves for Ironveld, Itaconix, Jersey Oil and Gas, Safestay, Galileo Resources, and Iofina. Iofina reported 393.3 tonnes H1 2026 and raised guidance to 460-485 tonnes.

$IRONMed

Ironveld shares jump 32% at 0.025p as processing plant hits sustained production

Ironveld PLC (AIM:IRON) shares rose 32% to 0.025p after the company said its dense media separation plant reached sustained production. It now runs 16 hours daily on double shift, processing 2.5-3.5 tonnes per hour and producing 1.4 tonnes/hour in-spec magnetite plus about 1 tonne/hour maghemite. Three clients secured, with a 5,000 tonnes/month buyer sampling; expansion options and Mintek study ongoing.

$IRONMed

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Disc Medicine (NASDAQ:IRON) reported updated clinical data at the 2026 EHA meeting in Stockholm. In RALLY-MF, DISC-0974 showed durable overall anemia responses in myelofibrosis across subgroups, including 55% major hemoglobin response in non-transfusion dependent patients and transfusion independence in 64% (TD Low) and 50% (TD High). In HELIOS, bitopertin sustained PPIX reductions and improved light tolerance with favorable longer-term safety. A corporate call is set for June 15.

$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) shareholders, alleging materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.

$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) investors over allegations of materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.